New research indicates that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a prominent medical journal demonstrates that while obese individuals can lose about a fifth of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals buying such medications must be cognizant of the danger of rapid rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
Such speed of regain means a reversion to original mass in about 18 months.
Weighing Therapies
The study, which looked at 37 of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
The team point out that individuals who shed pounds through diet and exercise usually experience a more gradual creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Nutrition scientists suggest the way of the injections accounts for the accelerated regain.
These medications mimic a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication leads to hunger is no longer kept in check, making binge eating much more probable."
A Chronic Disease?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts say that, due to the high risk of relapse, the treatment is often long-term.
This view is echoed by pharmaceutical companies, who state that the results "highlight the chronic nature of excess weight," comparing it to managing diseases like high blood pressure.
User Accounts
Individuals who have stopped the jabs describe a intense return of cravings.
"I experienced a switch flipping and you're instantly starving," described one woman.
The struggle is worsened if patients have not adopted lasting lifestyle or habit modifications during treatment.
Significant Use
Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is more common among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while these medications are effective agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on ongoing behavioural support.
